FDA grants clearance to Harbour’s IND for solid tumors therapy trial

The US Food and Drug Administration (FDA) has granted clearance to Harbour BioMed’s investigational new drug (IND) application enabling initiation of a Phase I study of HBM9033 to treat advanced solid tumors.